<DOC>
	<DOCNO>NCT00793195</DOCNO>
	<brief_summary>The aim study determine feasibility conduct trial examine efficacy ω3FA ( Omega-3 fatty acid ) contain balance lipid emulsion prevention progression PNALD infants Intestinal Failure/Short Bowel Syndrome ( SBS ) early liver dysfunction .</brief_summary>
	<brief_title>Can SMOFlipid® , A Composite Parenteral Nutrition Lipid Emulsion , Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants ?</brief_title>
	<detailed_description>Parenteral nutrition ( PN ) associate liver disease ( PNALD ) , remain primary cause morbidity mortality infant Short Bowel Syndrome ( SBS ) intestinal failure . Although , etiology likely multi-factorial , lipid within parenteral nutrition solution implicate development . The standard lipid use PN typically , soy base lipid ( eg : Intralipid® - Fresenius Kabi ) primarily contain omega-6 fatty acid ( ω6FAs ) . Animal human study suggest addition omega-3 fatty acid ( ω3FAs ) parenteral nutrition may decrease incidence hepatic injury , well beneficial immunologic effect . SMOFlipid® ( Fresenius Kabi ) composite lipid emulsion , contains polyunsaturated ω3 ω6FAs , monounsaturated FAs , well medium chain FAs integral constituent . All component ( Soy-bean oil , medium chain triglyceride , olive oil , fish oil ) use human , drug approve use child Europe . Based composition , believe lipid preparation potential prevent progression liver disease infant SBS demonstrate evidence liver dysfunction .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<criteria>1 . ≤ 24 month age enrollment 2 . Evidence early hepatic dysfunction Serum conjugate bilirubin ≥ 17 umol/L 2 consecutive reading 7 day apart No evidence sepsis Normal Temperature ( T 35.5C 38.0C ) Normal leukocyte count Normal platelet count No systemic septic symptom No prior administration Omegaven 3 . ≥ 40 % total calorie administer PN 4 . Meet one follow diagnostic category Short Bowel Syndrome Abdominal surgical procedure include gastroschisis closure mean percutaneous drainage procedure within past 6 month receive PN since surgery Intestinal Failure One follow diagnosis child dependent PN Gastrointestinal Motility Disorder Mucosal Enteropathy 5 . Expectation treat physician patient require PN least 3 week follow enrollment . 6 . Parents willing participate include randomization 1 . Sepsis Hemodynamic Instability cause . 2 . Coagulopathy ( Platelets ≤ 150 000 , INR ≥ 1.4 ) 3 . Hypersensitivity fish , egg soy protein active substance excipients 4 . Current enrollment another clinical trial involve surgical pharmacologic intervention 5 . Serum conjugate bilirubin &gt; 50 umol/L 6 . Hyperlipidaemia ( ) LDL ≥ 4 mmol/L HDL ≥ 2 mmol/L Total cholesterol ≥ 5 mmol/L Triglycerides ≥ 1.5 mmol/L 7 . Treatment intravenous NAcetylcysteine Ursodeoxycholic acid 8 . Renal insufficiency Creatinine ≥ 80 umol/L 9 . Disorders Fluid Balance ( ) Serum Sodium &lt; 130 mmol/L Serum Sodium &gt; 145 mmol/L 10 . Unstable condition Acute pulmonary edema Decompensated cardiac insufficiency Severe posttraumatic condition Uncompensated diabetes mellitus Acute myocardial infarction Stroke within 3 month Thromboembolic event within 3 month Metabolic acidosis Serum Bicarbonate &lt; 17 mmol/L</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Neonates</keyword>
	<keyword>Short Bowel Syndrome</keyword>
	<keyword>Intestinal Failure</keyword>
	<keyword>Liver Failure</keyword>
	<keyword>Parenteral Nutrition</keyword>
	<keyword>Intralipid</keyword>
	<keyword>SMOF</keyword>
</DOC>